Cervical cancer is the one of most common causes of cancer-related death in women. In Malaysia, cervical cancer is the second most common cancer among women following breast cancer. The rate increases after 30 years of age and peaks at 65 – 69 years. In Japan, the incident rate increases after 25 years of ages and peaks at 30-35 years. HPV causes virtually all cervical cancers and their precursors everywhere in the world. The HPV 16 and HPV 18 subtypes are most associated with cervical cancer. It is estimated that complete coverage with HPV vaccines in the female population could reduce up to 90% of cervical cancer incidence. Malaysia is the first country for the successful introduction of the National Immunization Program of HPV vaccine with amazing high coverage for target girls in Asia. Unfortunately, most of patients with invasive cervical cancer have not been screened. Most of advanced patients were diagnosed with such bleeding, pain and urinary problems. Primary treatment currently includes radical surgery and radiotherapy. However, concurrent radiotherapy and chemotherapy is standard in enhanced and maximal settings (resource) for women with stage IB to IVA disease (in ASCO Resource-Stratified Clinical Practice Guideline Management and Care of Women with Invasive Cervical Cancer, 2016 and Malaysia, Management of Cervical Cancer, Clinical Practice Guideline, 2015). Furthermore, ASCO guideline mentioned the use of Bevacizumab for patients with stage IVB and recurrent cancer. Also, in Japan, the use of Bevacizumab is approved for advanced and recurrent cancer. In this talk, I would like to introduce the preliminary trials of combination of paclitaxel and carboplatin is also effective in CCRT for the patients with advanced or recurrent cervical cancer, and the more possible effectiveness of Bevacizumab with chemotherapy for the patients with IVB and recurrent cancer.